Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 451 to 472 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
03/1/2020
14:36
FFWD released Portage news as RNS Includes this bit "As we move forward, we expect to announce news on subsequent milestones, as research has been progressing on all of our projects. It is our intent to focus the Company on projects that boost the immune system to combat cancer. (WE ENCOURAGE YOU TO VISIT THE REDESIGNED WEBSITE FOR MORE DETAILS ON THE DEVELOPMENT PROGRAMS AND INDIVIDUALS THAT ARE WORKING TO BRING THESE DISCOVERIES TO CANCER PATIENTS WORLDWIDE: WWW.PORTAGEBIOTECH.COM)"
the stigologist
01/1/2020
23:57
Company Operations Update "We are pleased to report several significant achievements since 2018 which, while resulting in our delay of filing of financial statements, have strengthened the position of Portage and its subsidiaries," said Ian Walters, MD, CEO of Portage. "The combined pipeline from our portfolio companies comprises one of the richest in oncology today. We're pleased to continue to support the work of our companies while identifying additional, new scientific and business development opportunities." "This past year, we completed several substantial acquisitions and investments, including the purchase of Intensity Holdings, as well as making significant financial investments in Stimunity and iOx Therapeutics," continued Dr. Walters. "In addition, clinical and regulatory progress was highlighted by Intensity's receipt of FDA Fast Track designation for its lead compound, and entry into a research collaboration with Merck. We are confident this collaboration will further the development of new potential treatments for patients with advanced solid tumors. We look forward to continuing our mission of providing funding, business and clinical counsel, and shared services to enable efficient, commercially-informed development of best-in-class therapies."
the stigologist
31/12/2019
12:46
Don't see the point of the RTO if we're delisted ? I guess the readmission process should be pretty straightforward and less costly than an IPO Even if it remains private they can still divest cash and shares to shareholders. Not too worried it's not a distressed debt situation just sloppy and tardy
the stigologist
31/12/2019
11:53
So what happens to Salvarx shares / shareholders? Presumably we become a private limited company?
dexdringle
31/12/2019
11:09
As noted in the Company's interim results for the six months ended 30 June 2019, the Company has been evaluating a number of potential acquisition opportunities. The Company is now pleased to announce that it is in advanced discussions with an acquisition target which is a leader in the field of oral immune therapies. Should this proposed acquisition proceed, the Board of SalvaRx anticipates making a further announcement early in the new year, setting out full details of the transaction. Despite efforts to conclude a reverse takeover before the cancellation date, it will not be possible to conclude the proposed transaction before 10 January 2020. On this basis, the cancellation of the admission to trading of the Ordinary Shares on AIM is expected to take effect from 7.00 a.m. on 10 January 2020.
the stigologist
31/12/2019
10:32
Notification received that these will be de-listed from AIM on 10th January. So much for them becoming a 'cash shell' ? Is anyone in here still holding these ??
dexdringle
22/8/2019
10:38
Where did everyone go ? Salvx and Portage are now suspended (for different reasons). On the face of it, this isn't exactly encouraging. At best it is poor planning and organisation - never desirable.
dexdringle
08/8/2019
08:32
Great. My prediction from 9th July seems to be coming true as Portage are now in the $hit for not filing results on time. There can be only one reason for that - and you can bet your life that it isn't that the numbers are so fantastic they need to be double checked before release..... Is there a Portage Biotech forum somewhere on the interweb ?
dexdringle
09/7/2019
19:26
Mellon and Bailey only take a token £10k per year. And there is only one other director. They have stated the costs are next to nothing to run as it’s only a holding company all they have is a bunch of portage shares. Currently worth just over 12p to each salvarx share. As far as winding the company up. It’s not as though it’s a large complicated business. It could be wound up in 10 minutes for around £500 to delist and log it at company house. The holding shares could be sold in no time at all. But why would they do that ??? Even an Aim listing is worth around £500k as that is the current cost for a company to list on aim and that’s with several months wait . To any company that is going to list. I see it as coming back with a reverse takeover with one of Mellon’s many interests. He has majority share holdings in over 20 unlisted companies. A couple of these he has quoted as saying will list this year.
brave dave
09/7/2019
13:30
...but they haven't done anything. Not a sausage. There is no evidence whatsoever of them having tried to do anything. It is most odd. I still have my PORT too but the way things are going with my portfolio I expect those to halve any day soon...
dexdringle
09/7/2019
12:20
They clearly were trying to add value by doing a reverse, but that had risks.I still hold my PORT.
bscuit
09/7/2019
10:32
so it is a 'cash shell' with no cash ? Wouldn't it have been better to wind it up in January and save six months costs ? I am struggling to see how waiting six months has been in any way to the advantage of the shareholders (owners)…̷0;. Id like to see where the money has gone (and is going re redundancy payments etc). You were right. There was zero point holding these. I should have sold. Had they said "we are keeping sufficient Portage shares back to cover winding up costs" then obviously I would have. But they didn't say that.
dexdringle
09/7/2019
09:01
Directors' redundancy and loss of LTIP etc
bscuit
09/7/2019
08:37
Really ? It doesn't cost that much to wind up a company. It isn't as though there are administrators etc as with companies that have gone into liquidation due to failure. Doesn't SALV still own around 60M Portage shares with a value of around £4M (which is 10p worth per SALV share)?? This is making me think that they kept the rump of the Portage shares purely as a float to keep enough back to keep the salary band wagon rolling for a few more months otherwise what was the point ? I hope I'm wrong but this simply isn't making sense......
dexdringle
08/7/2019
21:17
Liquidation costs will haves significant effect
bscuit
08/7/2019
20:36
For "holders" read "owners".... Assume they will liquidate assets and distribute to shareholders. All a bit pointless keeping some of the Portage shares unless I'm missing something?
dexdringle
08/7/2019
20:21
But there is a risk of delisting G which means holders are denied realising their investment except when the company does a deal. I sold months ago.
bscuit
08/7/2019
20:07
... and maybe a lot more if Portage lists on NASDAQ/NYSE and newsflow is positive.
fig1
08/7/2019
19:48
.....but the company has at least 10p per shares worth of invested Portage shares doesn't it ?
dexdringle
08/7/2019
18:56
From results RNS on 28/6. The disposal and the demerger resulted in the divestment of substantially all of the Company's existing business, assets and investments. As such, the Company is now classified as an AIM Rule 15 cash shell and is required to make an acquisition or acquisitions which constitute a reverse takeover under AIM Rule 14 (or seek re-admission as an investing company (as defined under the AIM Rules)) on or before the date falling six months from completion of the disposal and the demerger (namely 9 July 2019). Failing which, the Ordinary Shares will be suspended from trading on AIM pursuant to AIM Rule 40. Admission to trading on AIM will be cancelled six months from the date of suspension should the reason for the suspension not have been rectified.
cottoner
26/6/2019
08:07
Intensity link up with Merck htTps://intensitytherapeutics.com/intensity-therapeutics-announces-clinical-collaboration-with-merck/
the stigologist
06/5/2019
13:35
https://twitter.com/jrobinson_ccc/status/1125371058721189888?s=19
fig1
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
ADVFN Advertorial
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200923 19:17:22